<clinical_study>
  <!-- This xml conforms to an XML Schema at:
    https://clinicaltrials.gov/ct2/html/images/info/public.xsd -->
  <required_header>
    <download_date>ClinicalTrials.gov processed this data on November 19, 2021</download_date>
    <link_text>Link to the current ClinicalTrials.gov record.</link_text>
    <url>https://clinicaltrials.gov/show/NCT04564664</url>
  </required_header>
  <id_info>
    <org_study_id>2017/7397/I</org_study_id>
    <nct_id>NCT04564664</nct_id>
  </id_info>
  <brief_title>High-flow Oxygen Therapy During Exercise in Idiopathic Pulmonary Fibrosis</brief_title>
  <official_title>High-flow Oxygen Therapy During Exercise in Idiopathic Pulmonary Fibrosis: a Crossover Clinical Trial</official_title>
  <sponsors>
    <lead_sponsor>
      <agency>Parc de Salut Mar</agency>
      <agency_class>Other</agency_class>
    </lead_sponsor>
    <collaborator>
      <agency>Hospitales Universitarios Virgen del Rocío</agency>
      <agency_class>Other</agency_class>
    </collaborator>
  </sponsors>
  <source>Parc de Salut Mar</source>
  <oversight_info>
    <has_dmc>No</has_dmc>
    <is_fda_regulated_drug>No</is_fda_regulated_drug>
    <is_fda_regulated_device>No</is_fda_regulated_device>
  </oversight_info>
  <brief_summary>
    <textblock>
      Objectives:&#xD;
&#xD;
        1. To evaluate endurance time during cardiopulmonary exercise test (CPET) performance&#xD;
           comparing standard oxygen therapy to high-flow nasal cannula (HFNC) oxygen therapy in&#xD;
           subjects with idiopathic pulmonary fibrosis (IPF) with exertional desaturation.&#xD;
&#xD;
        2. To assess oxygenation level (peripheral and muscular) as well as dyspnea and fatigue&#xD;
           during exercise in IPF subjects with exertional desaturation using oxygen&#xD;
           supplementation with HFNC compared with standard oxygen supplementation.&#xD;
&#xD;
      Method: multicenter crossover clinical trial. Patients with IPF presenting oxygen&#xD;
      desaturation during the six-minute walking test (6MWT) (SpO2 mean ≤ 85%) will be included&#xD;
      consecutively . Each subject evaluated will perform initially an incremental CPET to evaluate&#xD;
      the patient's maximum exercise capacity. Supplemental oxygen will be applied to maintain SpO2&#xD;
      &gt;85% with a Venturi mask. Maximum exercise capacity and the appropriate final oxygen&#xD;
      inspiratory fraction (FiO2) needed for the following tests will be determined.&#xD;
&#xD;
      Posteriorly each patient will perform two constant load CPET (at 75% of the maximum workload&#xD;
      achieved with the incremental CPET); one with standard oxygen therapy and the other one with&#xD;
      HFNC oxygen therapy. Endurance time, dyspnea and leg fatigue and oxygen saturation&#xD;
      (peripheral and muscular) will be recorded.&#xD;
&#xD;
      Evaluation measures: Endurance time, dyspnea and leg fatigue (Borg scale), and oxygen&#xD;
      saturation.&#xD;
    </textblock>
  </brief_summary>
  <overall_status>Completed</overall_status>
  <start_date type="Actual">March 1, 2019</start_date>
  <completion_date type="Actual">March 30, 2021</completion_date>
  <primary_completion_date type="Actual">December 30, 2020</primary_completion_date>
  <phase>N/A</phase>
  <study_type>Interventional</study_type>
  <has_expanded_access>No</has_expanded_access>
  <study_design_info>
    <allocation>Randomized</allocation>
    <intervention_model>Crossover Assignment</intervention_model>
    <primary_purpose>Treatment</primary_purpose>
    <masking>None (Open Label)</masking>
  </study_design_info>
  <primary_outcome>
    <measure>Endurance time</measure>
    <time_frame>through study completion, an average of 1 week</time_frame>
    <description>Endurance time (s) during the constant load CPET performance with standard oxygen therapy compared to HFNC oxygen therapy</description>
  </primary_outcome>
  <secondary_outcome>
    <measure>Dyspnea and fatigue</measure>
    <time_frame>through study completion, an average of 1 week</time_frame>
    <description>Dyspnea and fatigue (Borg scale) at the end of the constant load CPET with standard oxygen therapy compared to HFNC oxygen therapy</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Oxygen saturation</measure>
    <time_frame>through study completion, an average of 1 week</time_frame>
    <description>Peripheral oxygen saturation (SpO2) during the constant load CPET with standard oxygen therapy compared to HFNC oxygen therapy</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Muscle oxygen saturation (StO2)</measure>
    <time_frame>through study completion, an average of 1 week</time_frame>
    <description>Muscle oxygen saturation (StO2) during the constant load CPET with standard oxygen therapy compared to HFNC oxygen therapy</description>
  </secondary_outcome>
  <number_of_arms>2</number_of_arms>
  <enrollment type="Actual">10</enrollment>
  <condition>Idiopathic Pulmonary Fibrosis</condition>
  <arm_group>
    <arm_group_label>High-flow nasal cannula oxygen therapy</arm_group_label>
    <arm_group_type>Other</arm_group_type>
  </arm_group>
  <arm_group>
    <arm_group_label>Standard oxygen therapy</arm_group_label>
    <arm_group_type>Other</arm_group_type>
  </arm_group>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>Oxygen</intervention_name>
    <description>High-flow nasal cannula oxygen therapy vs. standard oxygen therapy</description>
    <arm_group_label>High-flow nasal cannula oxygen therapy</arm_group_label>
    <arm_group_label>Standard oxygen therapy</arm_group_label>
  </intervention>
  <eligibility>
    <criteria>
      <textblock>
        Inclusion Criteria:&#xD;
&#xD;
          -  Subjects with IPF diagnosis according to the 2018 international consensus guidelines&#xD;
&#xD;
          -  Mean SpO2 ≤ 85% during the 6MWT performed under room air conditions&#xD;
&#xD;
        Exclusion Criteria:&#xD;
&#xD;
          -  Fibrotic interstitial lung diseases other than IPF&#xD;
&#xD;
          -  Chronic obstructive pulmonary disease (COPD)&#xD;
&#xD;
          -  Inability to perform a complete CPET due to osteo-articular or cognitive limitations&#xD;
&#xD;
          -  End-stage lung disease&#xD;
&#xD;
          -  Severe pulmonary hypertension&#xD;
      </textblock>
    </criteria>
    <gender>All</gender>
    <minimum_age>18 Years</minimum_age>
    <maximum_age>85 Years</maximum_age>
    <healthy_volunteers>No</healthy_volunteers>
  </eligibility>
  <overall_official>
    <last_name>Eva Balcells Vilarnau</last_name>
    <role>Principal Investigator</role>
    <affiliation>Hospital del Mar</affiliation>
  </overall_official>
  <overall_official>
    <last_name>Diego Agustín Rodriguez Chiariadia</last_name>
    <role>Study Director</role>
    <affiliation>Hospital del Mar</affiliation>
  </overall_official>
  <location>
    <facility>
      <name>Hospital del Mar</name>
      <address>
        <city>Barcelona</city>
        <zip>08003</zip>
        <country>Spain</country>
      </address>
    </facility>
  </location>
  <location_countries>
    <country>Spain</country>
  </location_countries>
  <verification_date>September 2020</verification_date>
  <study_first_submitted>September 14, 2020</study_first_submitted>
  <study_first_submitted_qc>September 21, 2020</study_first_submitted_qc>
  <study_first_posted type="Actual">September 25, 2020</study_first_posted>
  <last_update_submitted>August 7, 2021</last_update_submitted>
  <last_update_submitted_qc>August 7, 2021</last_update_submitted_qc>
  <last_update_posted type="Actual">August 13, 2021</last_update_posted>
  <responsible_party>
    <responsible_party_type>Sponsor</responsible_party_type>
  </responsible_party>
  <keyword>exertional desaturation</keyword>
  <keyword>high-flow nasal cannula</keyword>
  <condition_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Pulmonary Fibrosis</mesh_term>
    <mesh_term>Idiopathic Pulmonary Fibrosis</mesh_term>
    <mesh_term>Fibrosis</mesh_term>
  </condition_browse>
  <patient_data>
    <sharing_ipd>No</sharing_ipd>
  </patient_data>
  <!-- Results have not yet been posted for this study                                          -->
</clinical_study>

